Actively personalized vaccination trial for newly diagnosed glioblastoma

  title={Actively personalized vaccination trial for newly diagnosed glioblastoma},
  author={Norbert Hilf and Sabrina Kuttruff-Coqui and Katrin Frenzel and Valesca Bukur and Stefan Stevanovi{\'c} and C{\'e}cile Gouttefangeas and Michael Platt{\'e}n and Ghazaleh Tabatabai and Val{\'e}rie Dutoit and Sjoerd H. van der Burg and Per thor Straten and Francisco Mart{\'i}nez-Ricarte and Berta Ponsati and Hideho Okada and Ulrik N. Lassen and A. Admon and Christian Hermann Ottensmeier and Alexander Ulges and Sebastian Kreiter and Andreas von Deimling and Marco Skardelly and Denis Migliorini and Judith R. Kroep and Manja Idorn and Jordi Rod{\'o}n and Jordi Pir{\'o} and Hans Skovgaard Poulsen and Bracha Shraibman and Katy J McCann and Regina Mendrzyk and Martin L{\"o}wer and Monika Stieglbauer and Cedrik M. Britten and David Capper and Marij J. P. Welters and Juan Sahuquillo and Katharina Kiesel and Evelyna Derhovanessian and Elisa Rusch and Lukas Bunse and Colette Song and Sandra Heesch and Claudia Wagner and Alexandra Kemmer-Br{\"u}ck and Jorg Ludwig and John C. Castle and Oliver Schoor and Arbel D. Tadmor and Edward W. Green and Jens Fritsche and Miriam Meyer and Nina N. Pawlowski and Sonja Dorner and Franziska Hoffgaard and Bernhard R{\"o}ssler and Dominik Maurer and Toni Weinschenk and Carsten Reinhardt and Christoph Huber and Hans-Georg Rammensee and Harpreet Singh‐Jasuja and Uğur Şahin and Pierre-Yves Dietrich and Wolfgang Wick},
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential3. There is limited intratumoural infiltration of immune cells4 in glioblastoma and these tumours contain only 30–50 non-synonymous mutations5. Exploitation of the full repertoire of tumour antigens—that is, both… 

Personalized vaccines use tumour fingerprint to target glioblastoma

The results suggest that personalized neoantigen vaccination is a promising therapy for glioblastoma, but the authors note that further trials are needed to confirm the efficacy of this approach and to determine its place among other treatments.

New emerging targets in cancer immunotherapy: the role of neoantigens

The promises and challenges for using neoantigens as emergent targets to personalise and guide cancer immunotherapy in a broader set of cancers are discussed.

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives

It is argued that shortcomings of current immune therapies in glioblastoma are related to three major determinants of resistance, namely: low immunogenicity; immune privilege of the central nervous system; and immunosuppressive micro-environment.

Immunotherapy for Glioblastoma: Current Progress and Challenges

The primary ongoing immunotherapy candidates for glioblastoma are reviewed with a focus on immune checkpoint inhibitors, myeloid-targeted therapies, vaccines and chimeric antigen receptor (CAR) immunotherapies.

Emerging targets for anticancer vaccination: IDH

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

An overview of the complex process that is necessary to generate a personalized neoantigen vaccine, the types of vaccine-induced T cells that are found within tumours and outline strategies to enhance the T cell responses are provided.

Personalized neoantigen vaccines: a glimmer of hope for glioblastoma

Early-phase clinical trials of GBM neoantigen vaccines have shown promising clinical outcomes and therefore, its rapid clinical development is warranted, and increase in the clinical trials is expected.

Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy.

New developments in the application of immune checkpoint blockade are summarized, from biomarker-driven patient selection to the timing of treatment, and novel work in personalized immune-oncology is summarized by reviewing work in cancer immunogenomics-drive neoantigen vaccine studies.



An immunogenic personal neoantigen vaccine for patients with melanoma

The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.

Concepts in glioma immunotherapy

Immunotherapeutic concepts in neurooncology have been developed for many decades but have mainly been hampered by poor definition of relevant antigens and selective measures to target the central

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

IMA950 plus GM-CSF was well-tolerated with the primary immunogenicity endpoint of observing multi-TUMAP responses in at least 30% of patients exceeded, and further development of IMA950 is encouraged.

Genetic basis for clinical response to CTLA-4 blockade in melanoma.

These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA- 4 agents are being considered.

Vaccine-based immunotherapeutic approaches to gliomas and beyond

Preclinical trial data suggest that addition of immunomodulatory reagents such as immune checkpoint inhibitors, transforming growth factor-β inhibitors, signal transducer and activator of transcription 3 inhibitors, or modifiers of tryptophan metabolism could augment the therapeutic activity of vaccination and overcome glioma-associated immunosuppression.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

The first-in-human application of individualized mutanome vaccines in melanoma is reported, demonstrating that individual mutations can be exploited and opening a path to personalized immunotherapy for patients with cancer.

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival are identified.

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

It is provided proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation, leading to clinically and immunologically significant responses.